60699-67-4

Basic information

• Product Name: 3-(oxiran-2-yl)pyridine
• Synonyms: 3-(oxiran-2-yl)pyridine;3-(2-oxiranyl)Pyridine
• CAS NO: 60699-67-4
• Molecular Formula: C₇H₇NO
• Molecular Weight: 121.13658
• Mol File: 60699-67-4.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(oxiran-2-yl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(oxiran-2-yl)pyridine(60699-67-4)
• EPA Substance Registry System: 3-(oxiran-2-yl)pyridine(60699-67-4)

Safety Data

• Hazardous Substances Data: 60699-67-4(Hazardous Substances Data)

Upstream product

• 500-22-1 3-pyridinecarboxaldehyde 
• 3086-29-1 trimethylsulfonium chloride 
• 2181-44-4 trimethylsulfonium methylsulfate 
• 17694-68-7 3-(2-bromoacetyl)pyridine hydrobromide 
• 2181-42-2 trimethylsulphonium iodide 
• 118838-57-6 (1-R)-2-bromo-1-(3-pyridinyl)-1-ethanol 

Downstream Products

• 91800-29-2 2-(propylamino)-1-(pyridin-3-yl)ethan-1-ol 
• 793652-84-3 4'-(2-{[2-hydroxy-2-(3-pyridyl)ethyl]amino}ethyl)-2-(2-pyridyl)acetanilide 
• 329281-07-4 (S)-3-(2-oxiranyl)pyridine 
• 40594-83-0 1-pyridin-3-yl-ethane-1,2-diol 

Relevant articles and documents

AZEPINO [4, 5-B] INDOLES AND METHODS OF USE

This disclosure relates to new azepino[4,5-b]indole compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new 1, 2,3,4,5, 6-tetrahydroazepino[4,5-b]indoles. Pharmaceutical compositions are also provided.

HETEROCYCLIC COMPOUNDS

The invention is related to novel substituted diazaheterocycles useful as effective antihypercholesterolemic agents, methods of their preparation, and pharmaceutical compositions containing them.

5- substituted tetralones as inhibitors of ras farnesyl trransferase

The present invention provides novel 5-substituted tetralones of Formulas (I), (II), (III) and (IV) and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis. Specifically, the present invention relates to compounds that inhibit the farnesyl transferase enzyme.